SCHEMBL516151

SCHEMBL516151

Cc1cccc(OCCO)c1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1B P28222 1/20 0.62
MAPT P10636 3/20 0.53
KDM4E B2RXH2 1/20 0.53
GAA P10253 1/20 0.53
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 3/20 0.49
PPARG P37231 2/20 0.49
PPARD Q03181 2/20 0.49
PPARA Q07869 2/20 0.49
MAPK1 P28482 2/20 0.49
TSHR P16473 2/20 0.49
HTT P42858 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A1 P00352 3/20 0.47
HTR1A P08908 2/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4743007 0.89 HTR1B (0.59) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL5929458 0.87 HTR1B (0.71) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL8956316 0.87 HTR1B (0.57) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL515977 0.83 ALDH1A1 (0.62) MAPTKDM4EGAAKMT2ASMN1; SMN2
SCHEMBL2090753 0.83 HTR1B (0.56) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL28298076 0.82 ALDH1A1 (0.50) HTR1BMAPTKDM4EGAASMN1; SMN2
SCHEMBL18152143 0.82 IDO1 (0.49) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL7216294 0.82 HTR1B (0.65) HTR1BMAPTKDM4EGAAMEN1
SCHEMBL24699931 0.81 CYP1A2 (0.47) HTR1BMAPTKDM4EGAAKMT2A
SCHEMBL13555092 0.81 HTR7 (0.43) HTR1BMAPTKDM4EGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111465589-B Compound having fluorene skeleton and method for producing same 帝人株式会社 2024-01-05 CN disclosed
US-11339249-B2 Compound having fluorene skeleton, and method for manufacturing same TEIJIN LIMITED (JP) 2022-05-24 US disclosed
EP-3747856-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME Teijin Limited (JP) 2020-12-09 EP disclosed
US-20200354517-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME TEIJIN LIMITED (JP) 2020-11-12 US disclosed
CN-111465589-A Compound having fluorene skeleton and method for producing same 帝人株式会社 2020-07-28 CN disclosed
WO-2020085222-A1 CRYSTAL OF COMPOUND HAVING FLUORENE SKELETON AND METHOD FOR PRODUCING SAME 帝人株式会社 2020-04-30 WO disclosed
WO-2019151264-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME 帝人株式会社 2019-08-08 WO disclosed
EP-2626398-B1 THERMOCHROMIC COLOR-MEMORY COMPOSITION AND THERMOCHROMIC COLOR-MEMORY MICROCAPSULE PIGMENT ENCAPSULATING THE SAME PILOT INK CO LTD (JP) 2018-01-24 EP disclosed
US-9062028-B2 Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-06-23 US disclosed
US-9062028-B2 Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-06-23 US disclosed
WO-2008097483-A2 METHODS FOR PREPARING ARYL-SUBSTITUTED KETOPHOSPHONATES NEUROGEN CORPORATION (US) 2008-08-14 WO disclosed
EP-0702066-B1 Non-aqueous ink for ball point pen, and ball point pen MITSUBISHI PENCIL CO (JP) 2001-02-28 EP disclosed
EP-0702066-A2 Non-aqueous ink for ball point pen, and ball point pen MITSUBISHI PENCIL KABUSHIKI KAISHA (JP) 1996-03-20 EP disclosed
EP-0391942-A1 PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1990-10-17 EP disclosed
US-4935540-A OXIDIZING ARYLOXYETHANOL IN PRESENCE OF PALLADIUM AND THALLIU M ON CARBON CATALYST, ACIDIFYING EASTMAN CHEMICAL COMPANY 1990-06-19 US disclosed
WO-1989003378-A1 PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID EASTMAN KODAK COMPANY (US) 1989-04-20 WO disclosed
US-4804777-A OXIDATION OF ARYLOXYETHANOL USING PALLADIUM, SILVER, CARBON CATALYST EASTMAN KODAK COMPANY (US) 1989-02-14 US disclosed
EP-0011793-B1 PROCESS FOR PREPARING ARYLOXYACETIC ACIDS BAYER AG (DE) 1981-09-02 EP disclosed
US-4238625-A ACTIVATORS OF LEAD AND/OR BISMUTH AND/OR THEIR COMPOUNDS FOR OXIDATION WITH PLATINUM OR PALLADIUM CATALYST BAYER AKTIENGESELLSCHAFT (DE) 1980-12-09 US disclosed
EP-0011793-A1 Process for preparing aryloxyacetic acids BAYER AG (DE) 1980-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200354517-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME RFT1, AFF1, RER1 HTR1B 735/4885MAPT 2027/4885KDM4E 2520/4885
US-11339249-B2 Compound having fluorene skeleton, and method for manufacturing same RFT1, AFF1, RER1 HTR1B 735/4885MAPT 2027/4885KDM4E 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.